{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-213940","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2023-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.054690+00:00","generated_at":"2026-06-11T08:20:23.960571+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Soleno Therapeutics appoints Matthew Pauls to Board, expanding to seven directors","bullets":["Board increased to seven; Matthew Pauls appointed as Class II director effective August 15, 2023, term expiring 2026.","Pauls brings 30+ years biopharma experience; currently CEO of Savara Inc. (NASDAQ: SVRA) and former CEO of Strongbridge Biopharma.","Granted option for 15,000 shares vesting monthly over 4 years under the Company's 2014 equity plan.","Appointment comes as Soleno advances DCCR for Prader-Willi syndrome toward planned regulatory filing and potential approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-213940","json":"https://secwatch.observer/filing/0001193125-23-213940.json","markdown":"https://secwatch.observer/filing/0001193125-23-213940.md","text":"https://secwatch.observer/filing/0001193125-23-213940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312523213940/0001193125-23-213940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312523213940/d523594d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T08:20:23.960571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bdee5d0fba","claim":"Matthew Pauls was appointed as Director at SOLENO THERAPEUTICS INC.","evidence_excerpt":"appointed Mr. Matthew Pauls to the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312523213940/0001193125-23-213940-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}